In collaboration with the Medical University Graz and the computational biology company Innophore, acib is offering a powerful drug discovery and repurposing platform. The platform consists of an advanced computational modeling technology and of a high-end BSL-3+ laboratory for in-vitro drug testing and access to patient material including virus isolates.
Background
The last Covid-19 pandemic demonstrated the need for rapid access to new drugs and diagnostics. By combining advanced computational modeling and a series of in-vitro assays established in a high-end BSL-3+ laboratory, available drugs and chemical compounds can be rapidly tested for antiviral activity including high-risk pathogens. The use of different in-vitro models along with cultured human organs (precision-cut organ slices) and human organ cultures reduces the need for animal models and provides a solid pre-clinical data base for drug repurposing and rapid clinical application.
Technology
We offer three phase in-vitro testing of antiviral drugs including evaluation of toxicity, evaluation of antiviral activity in different cell lines, and antiviral activity in cultured human organs (precision cut organ slices) and human organ cultures. The read-out is based on cytopathic effects, qPCR and plaque assays. In the high-end BSL-3+ laboratory, we can establish and characterize viral cultures from patient samples and test the relevance of different sub-strains. Viruses covered include influenza virus (H1N1 and H5N1), Mpox virus, Hanta virus, and SARS-CoV-2.
Offer
Experts:
Prof. Dr. Kurt Zatloukal, Dr. Christian GruberDevelopment status:
Ready for external servicesKeywords:
Biological Safety Lab, Structural Biology, Computational Modeling, In-vitro Drug Testing, High-risk Pathogens, Influenza, Hanta, Mpox, SARS-CoV-2, Patient Samples, Diagnostics, Personal Protective Equipment (PPE), Decontamination Technologies, Human Organ Cultures
Picture: acib
